JENBURKT PHARMACEUTICALS LTD. (JENBURPH)

BSE: ₹1,123.50
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement for giving notice for the purpose of transfer of unclaimed dividend and corresponding equity shares of the Company to IEPFA.

2026-05-27 15:33:35
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretraial Compliance Report for the financial year ended 31st March, 2026.

2026-05-07 18:28:46
Intimation Of Record Date And Cut-Off Date

The Company has fixed Friday, 28th August, 2026, as the Record date for the Payment of Dividend for the Financial Year 2025-26 as well as cut-off date for Remote e-voting and e-voting during the 41st AGM.

2026-05-06 14:59:30
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication for standalone Audited financial results for the quarter and financial year ended on 31st March, 2026.

2026-05-06 14:44:37
Announcement under Regulation 30 (LODR)-Dividend Updates

The Board of Director of the Company recommeded a dividend of Rs.20.70 (207%) per equity share of Rs.10/- each on 4413300 equity shares of the Company for the financial year 2025-26, Subject to the approval of the menbers it the ensuing 41st AGM of the Company.

2026-05-05 19:52:29
Announcement under Regulation 30 (LODR)-Change in Management

Re-appointment of Whole Time Director and CFO of the Company, subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.

2026-05-05 19:46:56
Standalone Audited Financial Results For The Quarter And Financial Year Ened On 31St March, 2026.

Standalone audited financial reults of the Company for the quarter and financial year ended on 31st March, 2026.

2026-05-05 19:35:12
2026-05-05 19:15:32
Board Meeting Intimation for Taking On Record The Audited Financial Results For The Quarter And Financial Year Ended On 31St March, 2026 And To Consider Recommendation Of Dividend, If Any.

the audited results for the quarter and financial year ended on 31st March, 2026 and to consider recommendation of dividend, if any.

2026-04-28 16:44:26
Disclosures Pursuant To SEBI Circular Dated 10Th August, 2021 :"Not A Large Corporate"

Pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that, for the financial year ended 31st March, 2026, Jenburkt pharmaceuticals Limited is "not a large corporate" as per applicability criteria mentioned in clause 2.11 of chapter XII therein.

2026-04-14 13:18:24

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 29.18 38.29 35.66 38.84 32.54 41.22 36.89 41.05 35.53 45.56 43.02 44.63
YOY Revenue Growth % -6.29% 6.8% 3.16% 10.35% 11.52% 7.64% 3.46% 5.68% 9.19% 10.53% 16.62% 8.73%
Other Income 1.04 1.10 1.35 1.19 1.41 1.85 1.58 1.88 2.06 2.08 1.82 4.35
Total Income 30.21 39.38 37.01 40.03 33.94 43.07 38.47 42.93 37.58 47.64 44.84 48.98
Total Expenses + 22.78 29.84 29.17 29.67 23.88 30.55 28.96 31.09 27.40 33.30 36.54 31.32
Cost of Materials Consumed 2.05 1.68 2.15 2.52 1.84 2.15 2.24 2.28 2.14 2.19 2.47 2.19
Employee Benefit Expense 9.66 10.89 11.56 10.38 10.67 12.52 10.92 11.43 11.72 13.93 14.71 9.52
Other Expenses 7.00 9.09 9.45 10.40 6.29 8.99 9.97 10.85 8.33 10.16 12.09 12.21
Operating Profit 6.39 8.44 6.49 9.18 8.66 10.67 7.93 9.96 8.12 12.25 6.48 13.31
OPM % 21.9% 22.1% 18.2% 23.6% 26.6% 25.9% 21.5% 24.3% 22.9% 26.9% 15.1% 29.8%
Profit Before Tax + 7.43 9.54 7.84 10.37 10.06 12.52 9.51 11.84 10.18 14.33 8.30 13.71
Tax Expense 2.06 2.22 2.44 2.48 2.65 2.92 3.01 3.30 2.39 4.17 2.37 2.86
Tax % 27.7% 23.3% 31.1% 24% 26.3% 23.3% 31.6% 27.9% 23.5% 29.1% 28.5% 20.9%
Profit After Tax 5.37 7.32 5.40 7.88 7.42 9.60 6.51 8.54 7.79 10.16 5.93 10.85
EPS (Basic) 12.17 16.59 12.25 17.86 16.80 21.75 14.75 19.34 17.66 23.03 13.44 24.58

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 168.74 151.69 141.97 136.75 123.98 109.29
YOY Revenue Growth % 11.24% 6.85% 3.82% 10.3% 13.44% -
Other Income 10.30 6.72 4.67 5.12 4.95 4.31
Total Income 179.04 158.41 146.63 141.87 128.93 113.60
Total Expenses + 128.57 114.48 111.46 109.01 99.06 91.96
Cost of Materials Consumed 8.99 8.51 8.39 11.12 11.74 6.78
Employee Benefit Expense 49.88 45.54 42.49 38.81 36.49 32.38
Other Expenses 42.79 36.11 35.95 34.57 28.80 26.98
Operating Profit 40.17 37.21 30.51 27.74 24.92 17.33
OPM % 23.8% 24.5% 21.5% 20.3% 20.1% 15.9%
Profit Before Exceptional 50.47 43.93 35.18 32.86 29.87 21.64
Exceptional Items -3.95 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 46.52 43.93 35.18 32.86 29.87 21.64
Tax Expense 11.78 11.87 9.20 8.26 7.57 5.14
Tax % 25.3% 27% 26.2% 25.1% 25.4% 23.7%
Profit After Tax 34.74 32.06 25.98 24.61 22.30 16.50
EPS (Basic) 78.71 72.65 58.86 53.90 48.58 35.96

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 130.92 139.65 55.37 60.72 67.05 40.46
Property, Plant & Equipment 19.22 14.43 9.97 10.26 9.95 8.51
Capital Work in Progress 46.12 40.28 1.24 0.96 0.21 0.38
Non-Current Investments 27.02 20.56 16.79 11.18 7.96 6.50
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.24 0.00 0.39 0.19 0.31 0.48
Current Assets + 95.09 56.53 109.73 81.09 75.90 79.92
Inventories 13.63 8.88 8.56 8.34 9.89 7.58
Trade Receivables 24.36 20.73 19.48 16.96 15.21 14.00
Cash and Cash Equivalents 5.58 7.36 4.13 3.66 5.03 2.49
Current Investments 0.00 0.00 0.00 0.00 0.00 0.25
LIABILITIES & EQUITY
Total Equity 197.04 171.78 144.94 122.39 117.38 98.47
Equity Share Capital 4.41 4.41 4.41 4.41 4.59 4.59
Other Equity 192.63 167.36 140.53 117.98 112.79 93.88
Non-Current Liabilities 5.83 5.59 3.78 3.66 4.29 3.99
Current Liabilities 23.15 18.82 16.38 15.76 21.28 17.93
Total Liabilities 28.97 24.41 20.16 19.42 25.57 21.91

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities 26.52 27.91 8.12 17.05 9.40 19.45
Cash from Investing Activities -19.45 -17.04 -0.58 2.62 -1.33 -18.78
Cash from Financing Activities -8.86 -7.62 -7.08 -21.04 -5.53 -0.71
Net Increase/Decrease in Cash -1.79 3.24 0.47 -1.37 2.54 -0.04